These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22065199)

  • 1. Temozolomide plus radiotherapy for glioblastoma in a Canadian province: efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation.
    Lam N; Chambers CR
    J Oncol Pharm Pract; 2012 Jun; 18(2):229-38. PubMed ID: 22065199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.
    Brandes AA; Franceschi E; Tosoni A; Benevento F; Scopece L; Mazzocchi V; Bacci A; Agati R; Calbucci F; Ermani M
    Cancer; 2009 Aug; 115(15):3512-8. PubMed ID: 19514084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
    Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
    Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT gene silencing and benefit from temozolomide in glioblastoma.
    Hegi ME; Diserens AC; Gorlia T; Hamou MF; de Tribolet N; Weller M; Kros JM; Hainfellner JA; Mason W; Mariani L; Bromberg JE; Hau P; Mirimanoff RO; Cairncross JG; Janzer RC; Stupp R
    N Engl J Med; 2005 Mar; 352(10):997-1003. PubMed ID: 15758010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
    Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
    Chinot OL; Barrié M; Fuentes S; Eudes N; Lancelot S; Metellus P; Muracciole X; Braguer D; Ouafik L; Martin PM; Dufour H; Figarella-Branger D
    J Clin Oncol; 2007 Apr; 25(12):1470-5. PubMed ID: 17442989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
    Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
    Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
    Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M
    J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
    Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.